The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
The initiative was announced at World Hypertension Congress, Chennai
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025
Standalone profit from operations for the quarter were Rs. 162 crores
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
The Q1 2025 also witnessed a successful launch of Allegra D
Subscribe To Our Newsletter & Stay Updated
